Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **topical combination medication** consisting of allantoin, coal tar, clioquinol, and triclosan, each with distinct dermatological actions. **Allantoin** is known for its keratolytic and skin-soothing properties, promoting wound healing and epithelialization. **Coal tar** acts as a keratolytic, anti-inflammatory, and antimicrobial agent, slowing excessive skin cell proliferation, reducing itching, inflammation, and scaling, and is frequently prescribed for chronic skin conditions like psoriasis and eczema[1][3][5][7]. **Clioquinol** is a halogenated hydroxyquinoline with antimicrobial and antifungal properties, often used in treating skin infections and inflammatory dermatoses. **Triclosan** is a broad-spectrum synthetic antimicrobial agent effective against bacteria and fungi; it is included in personal care and medical products primarily for its bactericidal, fungicidal, and biocidal activities[2][4][8]. This combination is primarily indicated for the topical treatment of dermatological conditions—such as psoriasis, eczema, seborrheic dermatitis, fungal or bacterial skin infections—where antimicrobial, anti-inflammatory, and keratolytic activities are required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allantoin + coal tar + clioquinol + triclosan.